Sientra Inc's silicone gel-filled breast implant for breast reconstruction or augmentation has been approved by the FDA, as long as the company carries out post-approval studies to assess the device's long-term effectiveness, safety, and rare disease outcomes. The implant is approved for females aged at least 22 years. These implants are surgically implanted either under the chest muscle or under breast tissue - the aim is to enlarge the breasts, or rebuild them after breast cancer surgery or some breast abnormality. This implant has an outer shell made of silicone, and is filled will silicone gel. Shells have either a smooth or textured surface, and come in various sizes. Including this latest approval, there are now three silicone gel-filled breast implants in America which are FDA-approved. They are made by Sientra, Mentor and Allergan. William Maisel, M.D., M.P.H., deputy director for science in the FDA's Center for Devices and Radiological Health, said: "Data on these and other approved silicone gel-filled breast implants continue to demonstrate a reasonable assurance of safety and effectiveness. "It's important to remember that breast implants are not lifetime devices. Women should fully understand risks associated with breast implants before considering augmentation or reconstruction surgery, and recognize that long-term monitoring is essential." Sientra submitted its request for approval by sending the FDA three years' worth of clinical data from 1,788 patients. Outcomes and complications did not differ significantly from other breast implant studies, or previous studies using the same implant, the FDA informs. The latest study also included data on capsular contracture (tightening of the area around the implant), re-operation, removing the implant, infection, and asymmetry. "The design of these post-approval studies will require Sientra to collect valuable safety information with adequate enrollment and follow-up. The FDA is committed to working with breast implant manufacturers to collect useful post-market data on long-term safety and effectiveness."
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor